ImmunityBio (IBRX) announced the official voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026. Shareholders approved all proposals presented, including the re-election of the company's nine director nominees and the ratification of its independent registered public accounting firm.
Key Details
- Board of Directors Re-Elected: All nine nominees, including Patrick Soon-Shiong, M.D., were re-elected to the Board to serve a one-year term until the 2027 annual meeting.
- Auditor Ratified: The appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was approved by stockholders.
- Shareholder Participation: Approximately 85% of outstanding shares of common stock were represented at the meeting, constituting a quorum.